Your browser is no longer supported. Please, upgrade your browser.
Settings
GNMK [NASD]
GenMark Diagnostics, Inc.
Index- P/E- EPS (ttm)-0.41 Insider Own3.60% Shs Outstand71.10M Perf Week-5.46%
Market Cap1.47B Forward P/E- EPS next Y-0.07 Insider Trans-19.48% Shs Float68.45M Perf Month45.68%
Income-25.20M PEG- EPS next Q-0.02 Inst Own98.73% Short Float10.33% Perf Quarter54.06%
Sales148.70M P/S9.88 EPS this Y9.40% Inst Trans5.93% Short Ratio7.00 Perf Half Y29.99%
Book/sh1.32 P/B14.81 EPS next Y70.80% ROA-15.90% Target Price21.00 Perf Year440.06%
Cash/sh1.83 P/C10.70 EPS next 5Y- ROE-48.20% 52W Range3.36 - 23.59 Perf YTD33.90%
Dividend- P/FCF- EPS past 5Y2.30% ROI-51.50% 52W High-17.13% Beta3.08
Dividend %- Quick Ratio3.80 Sales past 5Y23.50% Gross Margin38.80% 52W Low481.85% ATR1.49
Employees437 Current Ratio4.30 Sales Q/Q103.80% Oper. Margin-11.90% RSI (14)59.25 Volatility7.94% 8.49%
OptionableYes Debt/Eq0.75 EPS Q/Q77.60% Profit Margin-17.00% Rel Volume1.95 Prev Close18.80
ShortableYes LT Debt/Eq0.75 EarningsFeb 25 AMC Payout- Avg Volume1.01M Price19.55
Recom1.90 SMA209.85% SMA5022.41% SMA20038.13% Volume1,967,089 Change3.99%
Aug-05-20Reiterated Needham Buy $19 → $22
Jul-08-20Reiterated Needham Buy $15 → $19
May-05-20Reiterated Needham Buy $11 → $15
Feb-11-20Downgrade Raymond James Outperform → Mkt Perform
Dec-11-19Downgrade JP Morgan Overweight → Neutral
Feb-22-19Reiterated Needham Buy $12
Nov-03-17Reiterated Needham Buy $15 → $11
Nov-03-17Downgrade Raymond James Outperform → Mkt Perform
Sep-18-17Initiated BofA/Merrill Buy $13
Sep-13-17Reiterated Needham Buy $17 → $15
Aug-31-17Resumed BTIG Research Buy $13
Jun-13-17Reiterated Needham Buy $16 → $17
Jan-24-17Reiterated Needham Buy $13 → $15
Feb-24-16Reiterated Needham Buy $13 → $11
Oct-28-15Reiterated Needham Buy $16 → $13
May-06-15Reiterated Canaccord Genuity Buy $16 → $14
Apr-17-15Reiterated Canaccord Genuity Buy $17 → $16
Dec-19-13Initiated Needham Buy $17
Aug-08-13Reiterated Canaccord Genuity Buy $18 → $14
Apr-15-13Reiterated Canaccord Genuity Buy $14 → $18
Feb-25-21 04:05PM  
02:30PM  
Feb-22-21 04:05PM  
Feb-16-21 05:35PM  
04:03PM  
Feb-11-21 04:17PM  
11:56AM  
Jan-11-21 04:08PM  
Dec-29-20 02:38AM  
Dec-28-20 04:05PM  
Dec-22-20 01:48PM  
Nov-05-20 04:05PM  
Oct-30-20 07:53AM  
Oct-29-20 02:03AM  
Oct-28-20 04:05PM  
02:30PM  
Oct-21-20 12:32PM  
Oct-14-20 05:20PM  
Oct-09-20 09:59AM  
04:37AM  
Oct-08-20 04:05PM  
04:03PM  
Sep-29-20 10:50AM  
Sep-22-20 07:00AM  
Sep-16-20 10:08AM  
Sep-14-20 04:05PM  
Sep-07-20 01:53PM  
Aug-27-20 12:39PM  
Aug-17-20 08:00AM  
Aug-05-20 02:01AM  
Aug-04-20 05:20PM  
04:05PM  
Jul-29-20 04:05PM  
Jul-24-20 10:15AM  
Jul-22-20 12:22PM  
11:30AM  
Jul-21-20 04:05PM  
04:05PM  
Jul-14-20 06:56AM  
Jul-09-20 09:54PM  
Jul-08-20 04:18PM  
12:07PM  
07:31AM  
04:55AM  
Jul-07-20 04:05PM  
Jun-29-20 07:00AM  
Jun-28-20 04:07PM  
Jun-27-20 01:15PM  
Jun-19-20 12:16PM  
12:00PM  
Jun-16-20 08:00AM  
Jun-12-20 07:55PM  
Jun-10-20 08:35AM  
08:29AM  
May-28-20 10:30AM  
May-27-20 04:05PM  
May-26-20 08:49AM  
May-14-20 11:16AM  
May-11-20 04:01PM  
May-08-20 10:52AM  
May-07-20 10:39AM  
May-06-20 10:59PM  
04:01PM  
May-05-20 08:00AM  
04:01AM  
May-04-20 06:55PM  
04:05PM  
04:03PM  
Apr-27-20 12:31PM  
Apr-24-20 10:50AM  
Apr-23-20 10:01AM  
Apr-22-20 04:05PM  
Apr-20-20 07:54AM  
Apr-08-20 04:26PM  
07:53AM  
02:45AM  
Apr-07-20 04:03PM  
Mar-23-20 07:45PM  
09:31AM  
09:30AM  
Mar-22-20 08:19AM  
Mar-19-20 09:23PM  
Mar-11-20 12:47PM  
10:44AM  
10:18AM  
09:54AM  
09:06AM  
08:26AM  
08:00AM  
Mar-04-20 08:04AM  
Mar-02-20 05:35PM  
04:05PM  
04:03PM  
Feb-25-20 08:35AM  
Feb-24-20 12:30PM  
09:28AM  
Feb-18-20 04:05PM  
Feb-17-20 05:57AM  
Feb-10-20 05:30PM  
05:15PM  
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsFeb 25Sale19.162665,097278,253Feb 25 06:33 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsFeb 24Sale19.121633,117280,263Feb 24 06:04 PM
Gleeson MichaelSVP, Corp. AccountsFeb 24Sale19.122,46347,093410,493Feb 25 06:32 PM
Shaw ChristineVP, Assay DevelopmentFeb 24Sale19.122594,952105,621Feb 25 06:32 PM
Gleeson MichaelSVP, Corp. AccountsFeb 23Sale19.351,43227,709412,956Feb 25 06:32 PM
Shaw ChristineVP, Assay DevelopmentFeb 23Sale19.351663,212105,880Feb 25 06:32 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsFeb 22Sale20.362905,904281,496Feb 22 07:02 PM
Winkler Sarah HollisVP, Human ResourcesFeb 19Sale21.8065414,257158,683Feb 22 07:04 PM
Gleeson MichaelSVP, Corp. AccountsFeb 19Sale21.802,34051,012414,388Feb 22 07:03 PM
Jensen TylerSVP, Engineering and Tech DevFeb 18Sale21.6850010,840214,097Feb 22 06:59 PM
Jensen TylerSVP, Engineering and Tech DevFeb 11Sale22.0010,000220,000214,597Feb 16 05:17 PM
Jensen TylerSVP, Engineering and Tech DevFeb 04Sale14.695007,345224,597Feb 08 05:10 PM
Winkler Sarah HollisVP, Human ResourcesJan 27Sale14.0678311,009140,587Jan 29 05:14 PM
Shaw ChristineVP, Assay DevelopmentJan 27Sale14.06811,13979,796Jan 29 05:15 PM
Harkins Michael JohnSVP, SalesJan 27Sale14.061,11715,705144,742Jan 29 05:14 PM
Jensen TylerSVP, Engineering and Tech DevJan 27Sale14.063224,527225,097Jan 29 05:16 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesJan 27Sale14.061802,531144,965Jan 29 05:15 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsJan 26Sale15.196,21494,391261,106Jan 29 05:16 PM
Mendel ScottPresident & CEOJan 25Sale14.2364,975924,594478,028Jan 25 08:35 PM
Harkins Michael JohnSVP, SalesJan 25Sale14.227,338104,346145,859Jan 25 08:36 PM
Stier EricSVP & General CounselJan 25Sale14.2229,658421,737277,619Jan 25 08:35 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsJan 25Sale14.2223,764337,924267,320Jan 25 08:35 PM
Jensen TylerSVP, Engineering and Tech DevJan 25Sale14.2320,953298,161225,419Jan 25 08:37 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesJan 25Sale14.236,45891,897145,145Jan 25 08:36 PM
Winkler Sarah HollisVP, Human ResourcesJan 25Sale14.2210,317146,708141,370Jan 25 08:36 PM
Ek John FrederickChief Financial OfficerJan 25Sale14.2418,475263,084210,258Jan 25 08:36 PM
Gleeson MichaelSVP, Corp. AccountsJan 25Sale14.2233,027469,644397,978Jan 25 08:37 PM
Mendel ScottPresident & CEOJan 21Option Exercise0.00146,1720543,002Jan 21 08:09 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsJan 21Option Exercise0.0065,1850291,084Jan 22 06:25 PM
Harkins Michael JohnSVP, SalesJan 21Option Exercise0.0019,1660153,197Jan 25 08:36 PM
Stier EricSVP & General CounselJan 21Option Exercise0.0077,2400307,277Jan 25 08:35 PM
Jensen TylerSVP, Engineering and Tech DevJan 21Option Exercise0.0056,8640246,372Jan 25 08:37 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesJan 21Option Exercise0.0016,6660151,603Jan 25 08:36 PM
Winkler Sarah HollisVP, Human ResourcesJan 21Option Exercise0.0027,5110151,687Jan 25 08:36 PM
Ek John FrederickChief Financial OfficerJan 21Option Exercise0.0050,4490228,733Jan 25 08:36 PM
Gleeson MichaelSVP, Corp. AccountsJan 21Option Exercise0.0083,8360431,005Jan 25 08:37 PM
Jensen TylerSVP, Engineering and Tech DevJan 21Sale14.935007,465189,508Jan 25 08:37 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsJan 20Sale15.005,00075,000225,899Jan 22 06:25 PM
Mendel ScottPresident & CEOJan 19Sale14.5450,000727,000115,491Jan 21 08:09 PM
Jensen TylerSVP, Engineering and Tech DevJan 07Option Exercise11.9631,500376,665222,485Jan 08 06:01 PM
Jensen TylerSVP, Engineering and Tech DevJan 07Sale16.9932,477551,784190,008Jan 08 06:01 PM
Jensen TylerSVP, Engineering and Tech DevJan 06Sale16.0016,823269,168190,985Jan 08 06:01 PM
Jensen TylerSVP, Engineering and Tech DevDec 24Sale15.005007,500207,808Dec 29 06:32 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsDec 21Sale15.0015,000225,000230,899Dec 22 05:42 PM
Jensen TylerSVP, Engineering and Tech DevDec 10Sale12.795006,395208,308Dec 11 05:51 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesDec 07Sale13.9774210,366134,937Dec 09 05:24 PM
Shaw ChristineVP, Assay DevelopmentDec 07Sale13.972743,82879,877Dec 09 05:24 PM
Jensen TylerSVP, Engineering and Tech DevNov 27Sale12.425006,210208,186Dec 01 05:48 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsNov 25Sale12.725527,021245,899Nov 25 05:28 PM
Ek John FrederickChief Financial OfficerNov 24Sale13.171,41818,675178,284Nov 25 05:30 PM
Jensen TylerSVP, Engineering and Tech DevNov 24Sale13.171,13214,908208,686Nov 25 05:29 PM
Shaw ChristineVP, Assay DevelopmentNov 24Sale13.173554,67579,291Nov 25 05:29 PM
Mendel ScottPresident & CEONov 24Sale13.175,19068,352396,830Nov 25 05:29 PM
Stier EricSVP & General CounselNov 24Sale13.172,51233,083230,037Nov 25 05:28 PM
Gleeson MichaelSVP, Corp. AccountsNov 24Sale13.173,23442,592347,169Nov 25 05:28 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesNov 24Sale13.171,14415,066135,679Nov 25 05:29 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsNov 24Sale13.171,99426,261246,451Nov 24 07:53 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsNov 20Sale13.013664,762248,445Nov 24 07:53 PM
Mendel ScottPresident & CEONov 19Sale13.853,98755,220402,020Nov 20 06:09 PM
Stier EricSVP & General CounselNov 19Sale13.851,55521,537232,549Nov 20 06:09 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsNov 19Sale13.851,31018,144248,811Nov 20 06:10 PM
Ek John FrederickChief Financial OfficerNov 19Sale13.851,63722,672179,702Nov 20 06:10 PM
Gleeson MichaelSVP, Corp. AccountsNov 19Sale13.851,63722,672350,403Nov 20 06:10 PM
Jensen TylerSVP, Engineering and Tech DevNov 19Sale13.851,14615,872209,818Nov 20 06:08 PM
Winkler Sarah HollisVP, Human ResourcesNov 19Sale13.856569,086124,176Nov 20 06:09 PM
Jensen TylerSVP, Engineering and Tech DevNov 12Sale13.685006,840210,964Nov 13 05:34 PM
Stier EricSVP & General CounselNov 11Sale12.7759,293757,172234,104Nov 13 05:35 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesNov 03Sale12.732122,699136,823Nov 04 06:46 PM
Jensen TylerSVP, Engineering and Tech DevOct 29Sale11.325005,660211,464Oct 29 06:07 PM
Winkler Sarah HollisVP, Human ResourcesOct 27Sale11.347658,675124,832Oct 29 06:06 PM
Jensen TylerSVP, Engineering and Tech DevOct 27Sale11.342202,495211,964Oct 29 06:07 PM
Shaw ChristineVP, Assay DevelopmentOct 27Sale11.346877179,646Oct 29 06:09 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesOct 27Sale11.341772,007137,035Oct 29 06:10 PM
Harkins Michael JohnSVP, SalesOct 27Sale11.341,09212,383132,982Oct 29 06:12 PM
Jensen TylerSVP, Engineering and Tech DevOct 15Sale11.835005,915209,765Oct 16 05:01 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsOct 07Option Exercise12.7658,680748,786319,870Oct 09 06:35 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsOct 07Sale15.0069,7491,046,235250,121Oct 09 06:35 PM
Jensen TylerSVP, Engineering and Tech DevOct 01Sale14.465007,230210,265Oct 02 07:37 PM
Ek John FrederickChief Financial OfficerSep 22Sale13.8241,196569,329181,339Sep 24 05:58 PM
Jensen TylerSVP, Engineering and Tech DevSep 17Sale12.725006,360210,765Sep 18 05:39 PM
Ek John FrederickChief Financial OfficerSep 16Sale12.985,72374,285222,535Sep 18 05:40 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesSep 08Sale11.027708,485137,212Sep 10 06:16 PM
Shaw ChristineVP, Assay DevelopmentSep 08Sale11.022853,14179,714Sep 10 06:14 PM
Mitchell Brian AndrewSVP, OperationsSep 08Sale11.024,00044,080166,651Sep 10 05:45 PM
Jensen TylerSVP, Engineering and Tech DevSep 03Sale12.205006,100211,265Sep 04 05:44 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsAug 27Sale13.1089111,672261,190Aug 28 05:54 PM
Mendel ScottPresident & CEOAug 26Sale15.0250,000751,00081,690Aug 28 05:53 PM
Mitchell Brian AndrewSVP, OperationsAug 26Sale14.743,46451,059170,651Aug 26 06:32 PM
Mitchell Brian AndrewSVP, OperationsAug 25Sale14.142,08329,454174,115Aug 26 06:32 PM
Mendel ScottPresident & CEOAug 25Sale14.144,53264,082489,808Aug 26 06:30 PM
Stier EricSVP & General CounselAug 25Sale14.142,68437,952293,397Aug 26 06:29 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsAug 25Sale14.142,13030,118262,081Aug 26 06:28 PM
Jensen TylerSVP, Engineering and Tech DevAug 25Sale14.141,21117,124211,765Aug 26 06:27 PM
Ek John FrederickChief Financial OfficerAug 25Sale14.141,51521,422228,258Aug 26 06:18 PM
Shaw ChristineVP, Assay DevelopmentAug 25Sale14.143795,35979,999Aug 26 06:17 PM
Gleeson MichaelSVP, Corp. AccountsAug 25Sale14.142,90441,063352,040Aug 26 06:15 PM
O'Brien Scott AlexanderSVP, Global Mktg & Int'l SalesAug 25Sale14.141,22317,293137,982Aug 26 06:14 PM
Mitchell Brian AndrewSVP, OperationsAug 21Sale15.622,99746,813176,198Aug 24 06:11 PM
Mendel ScottPresident & CEOAug 20Sale15.412,98846,045494,340Aug 24 06:13 PM
Maderazo Alan BaerVP, Qual, Reg, & Clin AffairsAug 20Sale15.411,35320,850264,211Aug 24 06:12 PM